EU/3/19/2194

About

On 21 August 2019, orphan designation EU/3/19/2194 was granted by the European Commission to Neurocrine Therapeutics Limited, Ireland, for 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine for the treatment of congenital adrenal hyperplasia.

Key facts

Active substance
4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine
Disease / condition
Treatment of congenital adrenal hyperplasia
Date of first decision
21/08/2019
Outcome
Positive
EU designation number
EU/3/19/2194

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Neurocrine Therapeutics Limited
70 Sir John Rogerson's Quay
Dublin 2
D02 R296
Ireland
Tel: +1 858 617 7623
E-mail: nrai@neurocrine.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating